Related Experiment Video
Updated: May 24, 2026
04:11
Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
[Hepatitis B mortality in Brazil, 2000-2009]
Márcia de Cantuária Tauil1, Thiago Rodrigues de Amorim, Gerson Fernando Mendes Pereira
1Programa de Treinamento em Epidemiologia Aplicada aos Serviços do SUS, Ministério da Saúde, Brasília, Brazil. mctauil@hotmail.com
Cadernos De Saude Publica
|March 15, 2012
Summary
Hepatitis B virus (HBV) mortality in Brazil remained constant, with higher rates in males and the North region. Early diagnosis and prevention are crucial to reduce future HBV deaths.
Area of Science:
- Epidemiology
- Public Health
Context:
- The study analyzes mortality data from Brazil's Mortality Information System (MIS) between 2000 and 2009.
- Focuses on deaths associated with Hepatitis B Virus (HBV).
Purpose:
- To describe the mortality profile of HBV in Brazil, examining national and regional variations.
- To identify demographic factors influencing HBV-related mortality and potential years of life lost (PYLL).
Summary:
- Crude HBV mortality rates were constant nationwide, with hepatocellular carcinoma accounting for no more than 7% of HBV-associated deaths.
- Standardized mortality rates were highest in Northern Brazil. Proportional mortality was higher in males.
- In 2009, PYLL peaked in males aged 50-59 and females aged 40-49, with the largest increase in PYLL observed in males aged 60-69.
Impact:
- Highlights the need for enhanced HBV prevention strategies and improved access to early diagnosis.
- Aims to inform public health policies to reduce HBV mortality in Brazil over the next decades.
Related Concept Videos
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...